Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Resverlogix Announces Participation in Upcoming Conferences

Posted on: 13 Sep 16

CALGARY, Sept. 12, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) is pleased to announce its participation in the following industry conferences in the month of September.

Rodman & Renshaw 18th Annual Global Investment Conference


New York, NY.


September 13th, 2016

Presentation Time:

2:10pm EDT


Mr. Donald J. McCaffrey, President & Chief Executive Office

Webcast link:


BioPharm America 9th Annual International Partnering Conference


Boston, MA.


September 14th, 2016

Presentation Time:

12:00pm EDT


Mr. Kenneth Lebioda, Sr. VP Business & Corporate Development


52nd European Association for the Study of Diabetes (EASD) Annual Meeting


Munich, Germany


September 14th, 2016

Presentation Time:  

12:00pm CEST


Dr. Norman Wong, Chief Scientific Officer


"Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular Events (MACE) in diabetes patients with atherosclerosis via microbiome activity"


About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (RVX.TO).

For further information please visit

Follow us on Twitter: @Resverlogix_RVX (, or on our blog at

For further information please contact:

Investor Relations
Phone: 403-254-9252

For more information:

Editor's Details

Mike Wood

Last updated on: 13/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.